These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26517511)

  • 1. High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival.
    Yi S; Zou D; Li C; Zhong S; Chen W; Li Z; Xiong W; Liu W; Liu E; Cui R; Ru K; Zhang P; Xu Y; An G; Lv R; Qi J; Wang J; Cheng T; Qiu L
    Oncotarget; 2015 Dec; 6(39):42362-71. PubMed ID: 26517511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
    Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
    J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Wang L; Tang G; Medeiros LJ; Xu J; Huang W; Yin CC; Wang M; Jain P; Lin P; Li S
    Haematologica; 2021 May; 106(5):1381-1389. PubMed ID: 32273477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma.
    Cho YA; Hyeon J; Lee H; Cho J; Kim SJ; Kim WS; Ko YH
    Hum Pathol; 2021 Jul; 113():9-19. PubMed ID: 33771538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular-cytogenetic characterization of non-Hodgkin's lymphoma with double and cryptic translocations of the immunoglobulin heavy chain gene.
    Kanda-Akano Y; Nomura K; Fujita Y; Horiike S; Nishida K; Nagai M; Miura I; Nakamura S; Seto M; Iida S; Ueda R; Taniwaki M
    Leuk Lymphoma; 2004 Aug; 45(8):1559-67. PubMed ID: 15370207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-hit mantle cell lymphoma with MYC gene rearrangement or amplification: a report of four cases and review of the literature.
    Setoodeh R; Schwartz S; Papenhausen P; Zhang L; Sagatys EM; Moscinski LC; Shao H
    Int J Clin Exp Pathol; 2013; 6(2):155-67. PubMed ID: 23330001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 8. MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.
    Yan LX; Liu YH; Luo DL; Zhang F; Cheng Y; Luo XL; Xu J; Cheng J; Zhuang HG
    PLoS One; 2014; 9(8):e104068. PubMed ID: 25090026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.
    Li S; Lin P; Fayad LE; Lennon PA; Miranda RN; Yin CC; Lin E; Medeiros LJ
    Mod Pathol; 2012 Jan; 25(1):145-56. PubMed ID: 22002575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphomas with pseudo-double-hit BCL6-MYC translocations due to t(3;8)(q27;q24) are associated with a germinal center immunophenotype, extranodal involvement, and frequent BCL2 translocations.
    Johnson SM; Umakanthan JM; Yuan J; Fedoriw Y; Bociek RG; Kaiser-Rogers K; Sanmann JN; Montgomery ND
    Hum Pathol; 2018 Oct; 80():192-200. PubMed ID: 29902576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYC cytogenetic status correlates with expression and has prognostic significance in patients with MYC/BCL2 protein double-positive diffuse large B-cell lymphoma.
    Wang XJ; Medeiros LJ; Lin P; Yin CC; Hu S; Thompson MA; Li S
    Am J Surg Pathol; 2015 Sep; 39(9):1250-8. PubMed ID: 25828389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYC overexpression correlates with MYC amplification or translocation, and is associated with poor prognosis in mantle cell lymphoma.
    Choe JY; Yun JY; Na HY; Huh J; Shin SJ; Kim HJ; Paik JH; Kim YA; Nam SJ; Jeon YK; Park G; Kim JE
    Histopathology; 2016 Feb; 68(3):442-9. PubMed ID: 26100211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
    Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
    Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort Study.
    Schiefer AI; Kornauth C; Simonitsch-Klupp I; Skrabs C; Masel EK; Streubel B; Vanura K; Walter K; Migschitz B; Stoiber D; Sexl V; Raderer M; Chott A; da Silva MG; Cabecadas J; Müllauer L; Jäger U; Porpaczy E
    Medicine (Baltimore); 2015 Dec; 94(52):e2388. PubMed ID: 26717387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
    Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
    Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
    [No Abstract]   [Full Text] [Related]  

  • 16. Inferior survival in high-grade B-cell lymphoma with
    McPhail ED; Maurer MJ; Macon WR; Feldman AL; Kurtin PJ; Ketterling RP; Vaidya R; Cerhan JR; Ansell SM; Porrata LF; Nowakowski GS; Witzig TE; Habermann TM
    Haematologica; 2018 Nov; 103(11):1899-1907. PubMed ID: 29903764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
    J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-MYC and BCL2 translocation frequency in diffuse large B-cell lymphomas: A study of 97 patients.
    Akkaya B; Salim O; Akkaya H; Ozcan M; Yucel OK; Erdem R; Iltar U; Undar L
    Indian J Pathol Microbiol; 2016; 59(1):41-6. PubMed ID: 26960633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quadruple-hit pleomorphic mantle cell lymphoma with MYC, BCL2, BCL6, and CCND1 gene rearrangements.
    Liu W; Chen X; Fan J; Zhu M; Shen H; Chen X; Chen G; Duan Y; He B; Zeng Z; Wu D; Pan J; Huang H
    Br J Haematol; 2021 Nov; 195(4):634-637. PubMed ID: 34528238
    [No Abstract]   [Full Text] [Related]  

  • 20. Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma.
    Fiskvik I; Beiske K; Delabie J; Yri O; Spetalen S; Karjalainen-Lindsberg ML; Leppä S; Liestøl K; Smeland EB; Holte H
    Leuk Lymphoma; 2015 Jun; 56(6):1742-9. PubMed ID: 25284491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.